Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients

Palbociclib is an oral CDK4/6 inhibitor indicated in HR+/HER2- advanced or metastatic breast cancer in combination with hormonotherapy. Its main toxicity is neutropenia. The aim of our study was to describe the kinetics of circulating neutrophils from real-life palbociclib-treated patients. A popula...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Alexandre Le Marouille, Emma Petit, Courèche Kaderbhaï, Isabelle Desmoulins, Audrey Hennequin, Didier Mayeur, Jean-David Fumet, Sylvain Ladoire, Zoé Tharin, Siavoshe Ayati, Silvia Ilie, Bernard Royer, Antonin Schmitt
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	MDPI AG 2021-10-01
Edice:	Pharmaceutics
Témata:	palbociclib neutropenia pharmacokinetic/pharmacodynamic
On-line přístup:	https://www.mdpi.com/1999-4923/13/10/1708
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!